Monitor FDA communications regarding clinical hold resolution for simufilam, as positive news could drive significant upside. Track cash runway given accelerating burn rate; potential need for financing within 12 months if no partnership or approval milestone.
Price Chart
Executive Summary
Filana Therapeutics reported Q1 2026 net loss of $0.21 per share, beating consensus of -$0.23 by 8.7%, driven by reduced R&D spending after phasing out Alzheimer's program. The company remains under FDA clinical hold for its lead TSC-epilepsy candidate simufilam, with no revenue and cash burn of $8.9M in the quarter. A $31.25M legal settlement payment expected in Q2 will consume substantial cash reserves.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.21 vs consensus -$0.23 (beat 8.7%)
- No revenue (pre-commercial stage)
- Net loss improved to $10.3M from $23.4M YoY
- Cash and equivalents $86.6M at March 31, 2026
- Cash used in operations $8.9M in Q1
- Estimated cash at June 30, 2026: $47-50M, including $31.25M legal settlement payment
- FDA clinical hold on simufilam for TSC-related epilepsy remains unresolved
- R&D expenses down 67% YoY due to Alzheimer's program phase-out
Financial Impact
Net loss improvement of $13.1M YoY driven by cost reductions; cash burn expected to accelerate with $31.25M legal payment in Q2 2026
Risk Factors
- FDA clinical hold may not be resolved, delaying or terminating lead program
- Cash burn rate may necessitate dilutive financing
- No approved products or revenue; stock price highly sensitive to regulatory and pipeline updates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6500 (−5.59%) |
Sep 22, 2026 5w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6500 (−36.89%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6500 (+12.10%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6500 (−25.25%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6500 (−46.28%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6500 (+52.21%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6500 (−52.21%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6500 (+66.67%) |
Mar 10, 2026 33w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6500 (−72.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers